Please login to the form below

Not currently logged in
Email:
Password:

Sigma-Tau Pharmaceuticals appoints Dave Lemus chief operating officer

He takes over from Gregg Lapointe who has resigned

Dave Lemus has been appointed chief operating officer at Sigma-Tau Pharmaceuticals.

He joined the US rare diseases company in July 2011 as VP, finance and in his new role he takes over from Gregg Lapointe who has resigned.

President of Sigma-Tau Pharmaceuticals Professor Trevor Jones said: "We are delighted to appoint Dave to lead our efforts to expand the world-class rare disease business we have established in the US.

“Dave brings a wealth of relevant pharmaceutical and biotech experience from both the US and Europe. His appointment will serve to further strengthen our unwavering mission to serve the needs of rare disease patients."

Prior to joining Sigma-Tau Lemus was chief financial officer at German biotech company MorphoSys, where he launched Germany's first-ever biotechnology IPO in 1999.

Before this he held a variety of senior management roles at Hoffmann-La Roche and Lindt in Switzerland.

12th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics